Clinical Trial

Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM

Name: Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM — clinical trial record (NCT07728019)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.

Trial Details

NCT Number	NCT07728019
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions	CRC (Colorectal Cancer)
Enrollment	60 participants
Start Date	2026-07-22
Primary Completion	2029-06-30 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-27